TRAW— Traws Pharma, Inc.

MaterialsPharmaceuticals$8M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenue	$2.8M+1134.5%	$226K+0.0%	$226K+0.0%	$226K
Acquired in-process research and development	$117.5M	—	—	—
Research and development	$12.1M-5.5%	$12.8M+12.4%	$11.4M+0.2%	$11.4M
General and administrative	$8.5M-30.7%	$12.3M+35.1%	$9.1M+7.7%	$8.4M
Total operating expenses	$20.7M-85.5%	$142.6M+594.8%	$20.5M+3.4%	$19.9M
Loss from operations	-$17.9M+87.4%	-$142.4M-601.4%	-$20.3M-3.4%	-$19.6M
Change in fair value of warrant liability /Series A warrant and pre-funded warrant expense	$26.6M+208.7%	-$24.4M	—	—
Other income, net	$478K+65.4%	$289K-78.6%	$1.4M+103.6%	$663K
Net income (loss)	$9.2M+105.5%	-$166.5M-778.8%	-$18.9M	—
Net income (loss) attributable to common stockholders, basic	$6.9M+112.6%	-$54.7M-188.5%	-$18.9M	—
Net income (loss) attributable to common stockholders, diluted	$6.9M+112.6%	-$54.7M-188.5%	-$18.9M	—
Weighted-average shares of common stock outstanding, basic (in shares)	8.2M+429.9%	1.6M+84.9%	840K-96.0%	20.9M
Net income (loss) per share of common stock, basic (in dollars per share)	$0.83+102.4%	-$35.21-56.0%	-$22.57-2380.2%	-$0.91
Weighted-average shares of common stock outstanding, diluted (in shares)	8.4M+439.5%	1.6M+84.9%	840K-96.0%	20.9M
Net income (loss) per share of common stock, diluted (in dollars per share)	$0.82+102.3%	-$35.21-56.0%	-$22.57-2380.2%	-$0.91
Net income (loss) attributable to Series C Preferred stockholders, basic	$2.3M+102.1%	-$111.8M	—	—
Net income (loss) attributable to Series C Preferred stockholders, diluted	$2.3M+102.1%	-$111.8M	—	—
Weighted-average shares of Series C Preferred outstanding, basic (in shares)	7K-13.0%	8K	—	—
Weighted-average shares of Series C Preferred outstanding, diluted (in shares)	7K-13.0%	8K	—	—
Net income (loss) per share of Series C Preferred, basic (in dollars per share)	$333.77+102.4%	-$14085.00	—	—
Net income (loss) per share of Series C Preferred, diluted (in dollars per share)	$333.77+102.4%	-$14085.00	—	—

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 16 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.